MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells

  • Authors:
    • Dongxiao Liu
    • Qingmin Sun
    • Song Liang
    • Linlin Xu
    • Xuan Luo
    • Xiaomei Zhao
    • Xuerong Wang
    • Li Yang
  • View Affiliations

  • Published online on: November 21, 2012     https://doi.org/10.3892/mmr.2012.1191
  • Pages: 642-648
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNA-27a (miR‑27a) is an oncogene that contributes to drug resistance in various types of cancer. However, the involvement of miR‑27a in gastric cancer has yet to be elucidated. Perifosine is an alkylphospholipid exhibiting antitumor activity as shown in both preclinical studies and clinical trials. The effects of perifosine on gastric cancer have yet to be determined. Therefore, this study was conducted to detect the role of miR‑27a and perifosine in human gastric cancer. miR‑27a was found to be expressed in human gastric cancer tissues and cell lines by quantitative reverse-transcription polymerase chain reaction (qRT‑PCR). The correlation between miR‑27a expression and clinicopathological characteristics of gastric cancer. We also explored the growth inhibitory effect of perifosine on human gastric cancer cells with or without co‑targeting miR‑27a by sulforhodamine B (SRB) assay. The results showed that miR‑27a expression was significantly upregulated in gastric cancer tissues, compared with their non‑tumor adjacent tissues. High expression levels of miR‑27a were associated with poor tumor histological grade (P=0.037). MiR‑27a inhibitors suppressed the growth of MGC‑803 cells. Assay results showed that perifosine exerted its activity selectively on the AGS cell line and the growth inhibitory effect of perifosine was enhanced significantly in combination with miR‑27a inhibitors in MGC‑803 cells. In conclusion, our results demonstrated that miR‑27a may be a therapeutic target and potential prognostic biological marker in gastric cancer. MiR‑27a inhibitors alone or in combination with perifosine may be a novel therapeutic approach against gastric cancer.
View Figures
View References

Related Articles

Journal Cover

February 2013
Volume 7 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu D, Sun Q, Liang S, Xu L, Luo X, Zhao X, Wang X and Yang L: MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells. Mol Med Rep 7: 642-648, 2013
APA
Liu, D., Sun, Q., Liang, S., Xu, L., Luo, X., Zhao, X. ... Yang, L. (2013). MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells. Molecular Medicine Reports, 7, 642-648. https://doi.org/10.3892/mmr.2012.1191
MLA
Liu, D., Sun, Q., Liang, S., Xu, L., Luo, X., Zhao, X., Wang, X., Yang, L."MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells". Molecular Medicine Reports 7.2 (2013): 642-648.
Chicago
Liu, D., Sun, Q., Liang, S., Xu, L., Luo, X., Zhao, X., Wang, X., Yang, L."MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells". Molecular Medicine Reports 7, no. 2 (2013): 642-648. https://doi.org/10.3892/mmr.2012.1191